Tammy S. Neff joined Muhlenkamp & Company, Inc. in September 2003.
Her responsibilities are primarily research oriented, including evaluating company fi nancial statements, annual reports, and proxy statements; analyzing industry and company research reports; interviewing and visiting company management teams; and making investment recommendations for inclusion in the Muhlenkamp portfolios.
Transforming the Face of Medicine:
Advances in Biomedical Science
Advances in biomedical science are transforming the way healthcare is being provided. This booklet examines some breakthrough innovations, along with a look at some of the companies making these advancements. Areas of interest include:
• Personalized medicine;
• Cancer and targeted cancer therapies;
• Immune system;
• Viruses; and
• 3-D bioprinting.
Personalized medicine is the application of information learned from studying the human proteome. Scientifi c discoveries in the lab continue to make their way into clinical practice, ushering in a new era of medicine. Arriving at this point requires some background.
Gates Capital Management's ECF Value Funds have a fantastic track record. The funds (full-name Excess Cash Flow Value Funds), which invest in an event-driven equity and credit strategy, have produced a 12.6% annualised return over the past 26 years. The funds added 7.7% overall in the second half of 2022, outperforming the 3.4% return for Read More
[pdfjs-viewer url=https://www.valuewalk.com/wp-content/uploads/2014/12/250889879-Biomedical-Booklet.pdf viewer_width=700px viewer_height=800px fullscreen=true print=true download=true openfile=false]